Vertex Pharmaceuticals Scheduled to Report Q3 2026 Earnings
Vertex Pharmaceuticals (VRTX) is set to release its third-quarter 2026 financial results on Monday, November 2, following the close of the market. Investors are closely watching for performance metrics that align with current consensus estimates. Market analysts expect a revenue figure of approximately $3.43 billion, representing an 11.4% increase year-over-year. However, earnings per share (EPS) is projected to be $4.75, which would mark a slight decline of 1.0% compared to the same period last year.
Tickers: $VRTX